Verification evidence is still being completed.
PDF / print export
Hansa Biopharma
Lund, Sweden
- Verified lead
- Soren Tulstrup
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- President and CEO
- 2026 technical specialization
- Transplant Medicine, Rare Disease Immunology, Enzyme-Based Therapies, and Desensitization Treatment
- Review cycle
- May 2026
- Full address
- Scheelevagen 22, 223 63 Lund, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Hansa Biopharma contact page confirming the Lund address.
- Editorial note
- Hansa Biopharma is published because the official site confirms current leadership, Lund operating address, and a differentiated immunology and transplant therapeutics platform.
Transplant Medicine, Rare Disease Immunology, Enzyme-Based Therapies, and Desensitization Treatment
Official leadership disclosure, Official Lund contact disclosure, Clinical-stage biopharma platform claim
Hansa Biopharma is published because the official site confirms current leadership, Lund operating address, and a differentiated immunology and transplant therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lund, Sweden
Hansa Biopharma
Transplant Medicine, Rare Disease Immunology, Enzyme-Based Therapies, and Desensitization Treatment · Clinical-stage therapeutics platform
Hansa Biopharma runs rare disease therapeutics, transplant program development, and clinical immunology programs in Lund, Sweden.
- Lead
- Soren Tulstrup (verified ↗)
- Address
- Scheelevagen 22, 223 63 Lund, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Rare Disease Therapeutics · Transplant Program Development · Clinical Immunology Programs
- Founded
- 2007
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Soren Tulstrup
President and CEO
Full addressScheelevagen 22, 223 63 Lund, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Clinical-stage therapeutics platform
Lund, Sweden. Transplant Medicine, Rare Disease Immunology, Enzyme-Based Therapies, and Desensitization Treatment. Review completed on 21 Mar 2026.
Swedish corporate and clinical-development oversight
Official leadership disclosure, Official Lund contact disclosure, Clinical-stage biopharma platform claim
Transplant Medicine, Rare Disease Immunology, Enzyme-Based Therapies, and Desensitization Treatment
Hansa Biopharma is published because the official site confirms current leadership, Lund operating address, and a differentiated immunology and transplant therapeutics platform.
Editorial note
Hansa Biopharma is published because the official site confirms current leadership, Lund operating address, and a differentiated immunology and transplant therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Rare Disease Therapeutics
Transplant Program Development
Clinical Immunology Programs
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Therapeutics development workflow
Clinical program infrastructure
Immunology and transplant R&D systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Hansa Biopharma located?
- Hansa Biopharma operates from Scheelevagen 22, 223 63 Lund, Sweden, Lund, Sweden.
- Who runs Hansa Biopharma?
- Hansa Biopharma is led by Soren Tulstrup, President and CEO. Verified 21 Mar 2026.
- What does Hansa Biopharma do?
- Hansa Biopharma runs rare disease therapeutics, transplant program development, and clinical immunology programs in Lund, Sweden. Core capabilities: Rare Disease Therapeutics, Transplant Program Development, Clinical Immunology Programs.
Editorial context
Related technical briefs
Briefs that name Lund as a covered market or city.